BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 31754995)

  • 1. Mutation Yield of a Custom 212-Gene Next-Generation Sequencing Panel for Solid Tumors: Clinical Experience of the First 260 Cases Tested Using the JAX ActionSeq™ Assay.
    Selvam P; Hsiao MC; Omerza G; Bergeron D; Rowe S; Uvalic J; Soucy M; Peracchio M; Burns S; Meyers B; Prego M; Nie Q; Ananda G; Chandok H; Kelly K; Hesse A; Reddi HV
    Mol Diagn Ther; 2020 Feb; 24(1):103-111. PubMed ID: 31754995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular profiling of CNS tumors for the treatment and management of disease.
    Nie Q; Hsiao MC; Chandok H; Rowe S; Prego M; Meyers B; Omerza G; Hesse A; Uvalic J; Soucy M; Bergeron D; Peracchio M; Burns S; Kelly K; Rueter J; Reddi HV
    J Clin Neurosci; 2020 Jan; 71():311-315. PubMed ID: 31859178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular profiling of gynecologic cancers for treatment and management of disease - demonstrating clinical significance using the AMP/ASCO/CAP guidelines for interpretation and reporting of somatic variants.
    Nie Q; Omerza G; Chandok H; Prego M; Hsiao MC; Meyers B; Hesse A; Uvalic J; Soucy M; Bergeron D; Peracchio M; Burns S; Kelly K; Rowe S; Rueter J; Reddi HV
    Cancer Genet; 2020 Apr; 242():25-34. PubMed ID: 31992506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and validation of the JAX Cancer Treatment Profile™ for detection of clinically actionable mutations in solid tumors.
    Ananda G; Mockus S; Lundquist M; Spotlow V; Simons A; Mitchell T; Stafford G; Philip V; Stearns T; Srivastava A; Barter M; Rowe L; Malcolm J; Bult C; Karuturi RK; Rasmussen K; Hinerfeld D
    Exp Mol Pathol; 2015 Feb; 98(1):106-12. PubMed ID: 25562415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic profiling of esophageal squamous cell carcinoma (ESCC)-Basis for precision medicine.
    Yang JW; Choi YL
    Pathol Res Pract; 2017 Jul; 213(7):836-841. PubMed ID: 28554745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
    Liu J; Liu Y
    Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of actionable genetic alterations with targeted panel sequencing in children with relapsed or refractory solid tumors.
    Lee JW; Kim NKD; Lee SH; Cho HW; Ma Y; Ju HY; Yoo KH; Sung KW; Koo HH; Park WY
    PLoS One; 2019; 14(11):e0224227. PubMed ID: 31747416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multigene panel next generation sequencing in metastatic colorectal cancer in an Australian population.
    Nindra U; Pal A; Lea V; Lim SH; Wilkinson K; Asghari R; Roberts TL; Becker TM; Farzin M; Rutland T; Lee M; MacKenzie S; Ng W; Wang B; Lee CS; Chua W
    PLoS One; 2023; 18(10):e0292087. PubMed ID: 37796807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutation Yield of a 34-Gene Solid Tumor Panel in Community-Based Tumor Samples.
    Sanders H; Qu K; Li H; Ma L; Barlan C; Zhang X; Prentice J; Wolfson D; Crossley B; Sferruzza A; Sninsky J; Ross D; Grupe A; Catanese J; Hantash F; Waldman F
    Mol Diagn Ther; 2016 Jun; 20(3):241-53. PubMed ID: 27084556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations.
    George SL; Izquierdo E; Campbell J; Koutroumanidou E; Proszek P; Jamal S; Hughes D; Yuan L; Marshall LV; Carceller F; Chisholm JC; Vaidya S; Mandeville H; Angelini P; Wasti A; Bexelius T; Thway K; Gatz SA; Clarke M; Al-Lazikani B; Barone G; Anderson J; Tweddle DA; Gonzalez D; Walker BA; Barton J; Depani S; Eze J; Ahmed SW; Moreno L; Pearson A; Shipley J; Jones C; Hargrave D; Jacques TS; Hubank M; Chesler L
    Eur J Cancer; 2019 Nov; 121():224-235. PubMed ID: 31543384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The long tail of molecular alterations in non-small cell lung cancer: a single-institution experience of next-generation sequencing in clinical molecular diagnostics.
    Fumagalli C; Vacirca D; Rappa A; Passaro A; Guarize J; Rafaniello Raviele P; de Marinis F; Spaggiari L; Casadio C; Viale G; Barberis M; Guerini-Rocco E
    J Clin Pathol; 2018 Sep; 71(9):767-773. PubMed ID: 29535211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of multiple gene detection with a 22-gene panel in formalin-fixed paraffin-embedded specimens of 207 colorectal cancer patients.
    Gao XH; Yu GY; Hong YG; Lian W; Chouhan H; Xu Y; Liu LJ; Bai CG; Zhang W
    Int J Clin Oncol; 2019 Feb; 24(2):141-152. PubMed ID: 30612269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of the Oncomine
    Williams HL; Walsh K; Diamond A; Oniscu A; Deans ZC
    Virchows Arch; 2018 Oct; 473(4):489-503. PubMed ID: 30105577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating gene fusions in solid tumors - Clinical experience using an RNA based 53 gene next-generation sequencing panel.
    Selvam P; Kelly K; Hesse AN; Spitzer D; Reddi HV
    Cancer Genet; 2019 Apr; 233-234():32-42. PubMed ID: 31109592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical sequencing using a next-generation sequencing-based multiplex gene assay in patients with advanced solid tumors.
    Kou T; Kanai M; Yamamoto Y; Kamada M; Nakatsui M; Sakuma T; Mochizuki H; Hiroshima A; Sugiyama A; Nakamura E; Miyake H; Minamiguchi S; Takaori K; Matsumoto S; Haga H; Seno H; Kosugi S; Okuno Y; Muto M
    Cancer Sci; 2017 Jul; 108(7):1440-1446. PubMed ID: 28440963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Next-generation sequencing-based clinical sequencing: toward precision medicine in solid tumors.
    Wakai T; Prasoon P; Hirose Y; Shimada Y; Ichikawa H; Nagahashi M
    Int J Clin Oncol; 2019 Feb; 24(2):115-122. PubMed ID: 30515675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved Variant Detection in Clinical Myeloid NGS Testing by Supplementing a Commercial Myeloid NGS Assay with Custom or Extended Data Filtering and Accessory Fragment Analysis.
    Schejbel L; Novotny GW; Breinholt MF; El Fassi D; Schöllkopf C; Hogdall E; Nørgaard P
    Mol Diagn Ther; 2021 Mar; 25(2):251-266. PubMed ID: 33687704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatic Tumor Testing in Prostate Cancer: Experience of a Tertiary Care Center Including Pathologist-Driven Reflex Testing of Localized Tumors at Diagnosis.
    Prendeville S; Kaur H; Ansari S; Al Qa'qa' S; Stockley TL; Lajkosz K; van der Kwast T; Cheung CC; Selvarajah S
    Mod Pathol; 2024 Jun; 37(6):100489. PubMed ID: 38588883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation and Application of a Custom-Designed Targeted Next-Generation Sequencing Panel for the Diagnostic Mutational Profiling of Solid Tumors.
    Froyen G; Broekmans A; Hillen F; Pat K; Achten R; Mebis J; Rummens JL; Willemse J; Maes B
    PLoS One; 2016; 11(4):e0154038. PubMed ID: 27101000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance validation of an amplicon-based targeted next-generation sequencing assay and mutation profiling of 648 Chinese colorectal cancer patients.
    Wang Y; Liu H; Hou Y; Zhou X; Liang L; Zhang Z; Shi H; Xu S; Hu P; Zheng Z; Liu R; Tang T; Ye F; Liang Z; Bu H
    Virchows Arch; 2018 Jun; 472(6):959-968. PubMed ID: 29705968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.